Which has stronger valuation and earnings, SOLV or BLCO?

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.81 $1.56B $8.18 10.80 Bausch + Lomb $5.10B 1.19 -$360M -$0.48 N/A

Is SOLV or BLCO more profitable?

Solventum has a net margin of 17.26% compared to Bausch + Lomb's net margin of -3.21%. Solventum's return on equity of 25.09% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.26% 25.09% 8.78% Bausch + Lomb -3.21% 4.14% 1.93%

Does the media prefer SOLV or BLCO?

In the previous week, Solventum had 2 more articles in the media than Bausch + Lomb. MarketBeat recorded 3 mentions for Solventum and 1 mentions for Bausch + Lomb. Solventum's average media sentiment score of 0.47 beat Bausch + Lomb's score of 0.00 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bausch + Lomb 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BLCO or COO?

In the previous week, Cooper Companies had 31 more articles in the media than Bausch + Lomb. MarketBeat recorded 32 mentions for Cooper Companies and 1 mentions for Bausch + Lomb. Cooper Companies' average media sentiment score of 0.25 beat Bausch + Lomb's score of 0.00 indicating that Cooper Companies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cooper Companies 3 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BLCO or ALGN?

In the previous week, Align Technology had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 4 mentions for Align Technology and 1 mentions for Bausch + Lomb. Align Technology's average media sentiment score of 0.32 beat Bausch + Lomb's score of 0.00 indicating that Align Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Align Technology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MMSI or BLCO?

In the previous week, Merit Medical Systems had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 5 mentions for Merit Medical Systems and 1 mentions for Bausch + Lomb. Merit Medical Systems' average media sentiment score of 0.96 beat Bausch + Lomb's score of 0.00 indicating that Merit Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merit Medical Systems 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BLCO or ICUI?

In the previous week, ICU Medical had 1 more articles in the media than Bausch + Lomb. MarketBeat recorded 2 mentions for ICU Medical and 1 mentions for Bausch + Lomb. ICU Medical's average media sentiment score of 0.75 beat Bausch + Lomb's score of 0.00 indicating that ICU Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ICU Medical 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bausch + Lomb (BLCO) Competitors

$17.10 +0.16 (+0.94%)

Closing price 03:59 PM Eastern

Extended Trading

$17.10 +0.00 (+0.03%)

As of 04:10 PM Eastern

Compare

BLCO vs. SOLV, COO, ALGN, MMSI, and ICUI

Should you buy Bausch + Lomb stock or one of its competitors? Bausch + Lomb's main competitors and comparable companies include Solventum (SOLV), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), and ICU Medical (ICUI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Bausch + Lomb compare to Solventum?

Solventum (NYSE:SOLV) and Bausch + Lomb (NYSE:BLCO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Solventum had 2 more articles in the media than Bausch + Lomb. MarketBeat recorded 3 mentions for Solventum and 1 mentions for Bausch + Lomb. Solventum's average media sentiment score of 0.47 beat Bausch + Lomb's score of 0.00 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch + Lomb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.1% of Bausch + Lomb shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Solventum has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.81	$1.56B	$8.18	10.80
Bausch + Lomb	$5.10B	1.19	-$360M	-$0.48	N/A

Solventum has a net margin of 17.26% compared to Bausch + Lomb's net margin of -3.21%. Solventum's return on equity of 25.09% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.26%	25.09%	8.78%
Bausch + Lomb	-3.21%	4.14%	1.93%

Solventum currently has a consensus target price of $92.80, suggesting a potential upside of 5.09%. Bausch + Lomb has a consensus target price of $19.15, suggesting a potential upside of 12.72%. Given Bausch + Lomb's higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Solventum beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Cooper Companies?

Bausch + Lomb (NYSE:BLCO) and Cooper Companies (NASDAQ:COO) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Cooper Companies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, Cooper Companies had 31 more articles in the media than Bausch + Lomb. MarketBeat recorded 32 mentions for Cooper Companies and 1 mentions for Bausch + Lomb. Cooper Companies' average media sentiment score of 0.25 beat Bausch + Lomb's score of 0.00 indicating that Cooper Companies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cooper Companies	3 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cooper Companies has a net margin of 13.46% compared to Bausch + Lomb's net margin of -3.21%. Cooper Companies' return on equity of 10.90% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Cooper Companies	13.46%	10.90%	7.24%

Cooper Companies has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.19	-$360M	-$0.48	N/A
Cooper Companies	$4.09B	2.66	$374.90M	$2.93	19.54

Bausch + Lomb currently has a consensus price target of $19.15, suggesting a potential upside of 12.72%. Cooper Companies has a consensus price target of $71.47, suggesting a potential upside of 24.82%. Given Cooper Companies' higher probable upside, analysts plainly believe Cooper Companies is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cooper Companies	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.16

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 24.4% of Cooper Companies shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Comparatively, 2.1% of Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cooper Companies beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Align Technology?

Bausch + Lomb (NYSE:BLCO) and Align Technology (NASDAQ:ALGN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Align Technology has a net margin of 9.99% compared to Bausch + Lomb's net margin of -3.21%. Align Technology's return on equity of 15.86% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Align Technology	9.99%	15.86%	10.32%

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 88.4% of Align Technology shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 0.8% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Align Technology has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.19	-$360M	-$0.48	N/A
Align Technology	$4.03B	2.57	$410.35M	$5.75	25.16

Bausch + Lomb currently has a consensus target price of $19.15, indicating a potential upside of 12.72%. Align Technology has a consensus target price of $206.36, indicating a potential upside of 42.66%. Given Align Technology's stronger consensus rating and higher probable upside, analysts clearly believe Align Technology is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Align Technology	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Align Technology had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 4 mentions for Align Technology and 1 mentions for Bausch + Lomb. Align Technology's average media sentiment score of 0.32 beat Bausch + Lomb's score of 0.00 indicating that Align Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Align Technology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market.

Summary

Align Technology beats Bausch + Lomb on 15 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and Bausch + Lomb (NYSE:BLCO) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Merit Medical Systems presently has a consensus price target of $100.00, indicating a potential upside of 16.02%. Bausch + Lomb has a consensus price target of $19.15, indicating a potential upside of 12.72%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts plainly believe Merit Medical Systems is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merit Medical Systems	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Merit Medical Systems had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 5 mentions for Merit Medical Systems and 1 mentions for Bausch + Lomb. Merit Medical Systems' average media sentiment score of 0.96 beat Bausch + Lomb's score of 0.00 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merit Medical Systems	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Merit Medical Systems has a net margin of 9.22% compared to Bausch + Lomb's net margin of -3.21%. Merit Medical Systems' return on equity of 13.75% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merit Medical Systems	9.22%	13.75%	8.10%
Bausch + Lomb	-3.21%	4.14%	1.93%

Merit Medical Systems has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merit Medical Systems	$1.52B	3.40	$128.49M	$2.42	35.62
Bausch + Lomb	$5.10B	1.19	-$360M	-$0.48	N/A

Merit Medical Systems has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

99.7% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 0.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Merit Medical Systems beats Bausch + Lomb on 14 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to ICU Medical?

Bausch + Lomb (NYSE:BLCO) and ICU Medical (NASDAQ:ICUI) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Bausch + Lomb has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, ICU Medical has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Bausch + Lomb presently has a consensus target price of $19.15, indicating a potential upside of 12.72%. ICU Medical has a consensus target price of $192.80, indicating a potential upside of 20.54%. Given ICU Medical's stronger consensus rating and higher probable upside, analysts clearly believe ICU Medical is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
ICU Medical	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.89

ICU Medical has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.19	-$360M	-$0.48	N/A
ICU Medical	$2.23B	1.79	$730K	$1.18	135.55

In the previous week, ICU Medical had 1 more articles in the media than Bausch + Lomb. MarketBeat recorded 2 mentions for ICU Medical and 1 mentions for Bausch + Lomb. ICU Medical's average media sentiment score of 0.75 beat Bausch + Lomb's score of 0.00 indicating that ICU Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ICU Medical	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ICU Medical has a net margin of 1.39% compared to Bausch + Lomb's net margin of -3.21%. ICU Medical's return on equity of 7.91% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
ICU Medical	1.39%	7.91%	4.17%

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 96.1% of ICU Medical shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 2.1% of ICU Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

ICU Medical beats Bausch + Lomb on 15 of the 17 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6.11B	$5.37B	$7.11B	$22.72B
Dividend Yield	N/A	1.80%	2.53%	3.74%
P/E Ratio	-35.62	24.63	274.42	27.75
Price / Sales	1.20	41.67	600.72	20.15
Price / Cash	10.19	32.68	77.38	39.56
Price / Book	0.93	5.69	10.92	4.64
Net Income	-$360M	$152.11M	$3.50B	$1.08B
7 Day Performance	1.19%	-2.01%	-2.07%	-1.06%
1 Month Performance	-5.37%	-5.42%	-6.32%	-5.02%
1 Year Performance	15.89%	2.71%	8.92%	5.78%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	3.7029 of 5 stars	$17.10 +0.9%	$19.15 +12.0%	+15.6%	$6.11B	$5.10B	N/A	13,000
SOLV Solventum	1.5926 of 5 stars	$89.60 +1.1%	$92.80 +3.6%	+20.1%	$15.24B	$8.31B	10.95	20,000
COO Cooper Companies	4.3283 of 5 stars	$55.38 flat	$71.47 +29.0%	-15.7%	$10.53B	$4.24B	18.90	15,000	Trending News Analyst Revision
ALGN Align Technology	3.7225 of 5 stars	$146.78 +0.8%	$206.36 +40.6%	+14.0%	$10.51B	$4.14B	25.53	20,290	News Coverage
MMSI Merit Medical Systems	3.4995 of 5 stars	$87.50 +0.2%	$100.00 +14.3%	+5.0%	$5.22B	$1.52B	36.16	7,500	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. SOLV, COO, ALGN, MMSI, and ICUI

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Cooper Companies?

Summary

How does Bausch + Lomb compare to Align Technology?

Summary

How does Bausch + Lomb compare to Merit Medical Systems?

Summary

How does Bausch + Lomb compare to ICU Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. SOLV, COO, ALGN, MMSI, and ICUI

How does Bausch + Lomb compare to Solventum?

Does the media prefer SOLV or BLCO?

Do insiders & institutionals hold more shares of SOLV or BLCO?

Which has more risk and volatility, SOLV or BLCO?

Which has stronger valuation and earnings, SOLV or BLCO?

Is SOLV or BLCO more profitable?

Do analysts recommend SOLV or BLCO?

Summary

How does Bausch + Lomb compare to Cooper Companies?

Which has more volatility & risk, BLCO or COO?

Does the media favor BLCO or COO?

Is BLCO or COO more profitable?

Which has better valuation and earnings, BLCO or COO?

Do analysts recommend BLCO or COO?

Do insiders and institutionals hold more shares of BLCO or COO?

Summary

How does Bausch + Lomb compare to Align Technology?

Is BLCO or ALGN more profitable?

Do institutionals and insiders have more ownership in BLCO or ALGN?

Which has preferable earnings & valuation, BLCO or ALGN?

Do analysts rate BLCO or ALGN?

Does the media prefer BLCO or ALGN?

Which has more volatility & risk, BLCO or ALGN?

Summary

How does Bausch + Lomb compare to Merit Medical Systems?

Do analysts rate MMSI or BLCO?

Does the media refer more to MMSI or BLCO?

Is MMSI or BLCO more profitable?

Which has better earnings and valuation, MMSI or BLCO?

Which has more volatility & risk, MMSI or BLCO?

Do insiders & institutionals believe in MMSI or BLCO?

Summary

How does Bausch + Lomb compare to ICU Medical?

Which has more volatility and risk, BLCO or ICUI?

Do analysts prefer BLCO or ICUI?

Which has better earnings & valuation, BLCO or ICUI?

Does the media prefer BLCO or ICUI?

Is BLCO or ICUI more profitable?

Do insiders & institutionals believe in BLCO or ICUI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools